Gilead Sciences Inc (GILD)

79.46
1.80 2.20
NASDAQ : Health Care
Prev Close 81.24
Open 80.60
Day Low/High 79.37 / 80.84
52 Wk Low/High 77.92 / 120.37
Volume 19.34M
Avg Volume 9.76M
Exchange NASDAQ
Shares Outstanding 1.33B
Market Cap 108.93B
EPS 12.40
P/E Ratio 7.21
Div & Yield 1.88 (2.30%)

Latest News

5 Blue-Chip Breakouts to Buy This Summer

5 Blue-Chip Breakouts to Buy This Summer

Some of this month's most explosive moves are coming from large-cap stocks. Here's how to profit from five of them.

Buy Gilead Sciences While It's Wallowing

Buy Gilead Sciences While It's Wallowing

It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.

Jim Cramer's 'Mad Money' Recap: 'Good Enough' Is a Triumph

Jim Cramer's 'Mad Money' Recap: 'Good Enough' Is a Triumph

There were many earnings reports today, and many could've been worse, Cramer says.

S&P 500 Goes Nowhere as Earnings Drive Choppiness

S&P 500 Goes Nowhere as Earnings Drive Choppiness

A wave of key earnings report out overnight and this morning swept Wall Street away on Tuesday.

Stocks Trade Mixed as Crude Settles Under $43

Stocks Trade Mixed as Crude Settles Under $43

Stocks fluctuate Tuesday as crude closes under $43 a barrel for the first time since April.

Jim Cramer Likes UTX, Says Gilead Has Peaked, Sees a Bottom for Oil

Jim Cramer Likes UTX, Says Gilead Has Peaked, Sees a Bottom for Oil

United Technologies is taking share from competitors like General Electirc.

Gilead Sciences (GILD) Stock Plunges on Q2 Results, RBC Cuts Price Target

Gilead Sciences (GILD) Stock Plunges on Q2 Results, RBC Cuts Price Target

Gilead Sciences (GILD) stock is retreating Tuesday afternoon after the company lowered its full-year sales outlook.

3 Stocks Dragging The Health Care Sector Downward

3 Stocks Dragging The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Cramer: Winners and Losers in the Earnings Game

Cramer: Winners and Losers in the Earnings Game

Good enough, tied with a good story, is pushing post-earnings bumps today.

Dow Slides as McDonald's Disappoints, New Home Sales Climb

Dow Slides as McDonald's Disappoints, New Home Sales Climb

Stocks trade mixed Tuesday as a number of positive and negative earnings report keep traders active.

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.

Stock Futures Mixed as Fed Meets, Verizon and McDonald's Tumble

Stock Futures Mixed as Fed Meets, Verizon and McDonald's Tumble

Stock futures are mixed as investors stay on the sidelines ahead of the kickoff to the Federal Reserve's July meeting.

Cramer: For Texas Instruments and Gilead, It's all About Trajectory

Cramer: For Texas Instruments and Gilead, It's all About Trajectory

One is rising on a minor sales bump while the other is falling despite solid results; and here is why.

Rev's Forum: A Hard Market to Embrace

Rev's Forum: A Hard Market to Embrace

With chaos blaring in the headlines, market players simple shrug.

Wait for Another 10% Drop In Gilead Before Buying

Wait for Another 10% Drop In Gilead Before Buying

The stock is poised to test support at around $78 per share, or 10% lower. At that point, Gilead stock is safe to buy. Anything in between is trap.

Post-Market Activity Shows Gilead (GILD) Down

Post-Market Activity Shows Gilead (GILD) Down

Trade-Ideas LLC identified Gilead (GILD) as a post-market laggard candidate

Gilead Lowers Product Sales Guidance on Weak Hepatitis C Sales

Gilead Lowers Product Sales Guidance on Weak Hepatitis C Sales

Gilead's stock trades at a discount to other biotech peers because its drug research pipeline lacks the blockbusters needed to make up for slowing sales from its hepatitis C franchise.

Gilead Sciences Announces Third Quarter 2016 Dividend

Gilead Sciences Announces Third Quarter 2016 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Second Quarter 2016 Financial Results

Gilead Sciences Announces Second Quarter 2016 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2016.

Is Timeframe on Your Side?

Is Timeframe on Your Side?

Earnings reports will test the timeframe mettle for some investors and traders.

Gilead Readying for Earnings Report

Gilead Readying for Earnings Report

The biopharmaceutical giant is getting ready to report its second-quarter results, which are set to be released after Monday's close.

Morning Movers: YHOO, VZ, DHR, GILD

Morning Movers: YHOO, VZ, DHR, GILD

Verizon won the competitive bidding process for Yahoo and will pay the company $4.8 billion for its internet properties.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

Verizon strikes a $4.8 billion deal to acquire Yahoo!'s core operations, while Tesla and SolarCity are closer to a merger agreement.

What to Watch This Week: Apple, Facebook, Alphabet Report Earnings; Federal Reserve Meeting

What to Watch This Week: Apple, Facebook, Alphabet Report Earnings; Federal Reserve Meeting

A slew of corporate earnings and closely watched Federal Reserve meeting are in focus for the week of July 25.

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week

Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say?

Morgan Stanley believes these stocks will have negative earnings catalysts, but how does the technical analysis stack up?

Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report

Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report

Gilead Sciences (GILD) is scheduled to report earnings on Monday, July 25 after the market close.